PROTONIX I.V. Rx

Select the drug indication to add to your list

PROTONIX I.V.

Hyperacidity, GERD, and ulcers
Only 4 drugs may be compared at once

Generic Name and Formulations:

Pantoprazole (as sodium) 40mg; per vial; pwd for IV infusion after reconstitution and dilution; contains edetate disodium.

Company:

Pfizer Inc.

Select therapeutic use:

Indications for PROTONIX I.V.:

Short-term treatment (7–10 days) of GERD associated with a history of erosive esophagitis. Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).

Adult:

≥18yrs: GERD: 40mg once daily for 7–10 days; switch to tabs or oral suspension as soon as possible. Pathological hypersecretory conditions: 80mg every 8–12 hrs; usual max 240mg/day or 6 days' treatment.

Children:

<18yrs: not established.

Warnings/Precautions:

Symptomatic response does not preclude gastric malignancy. Discontinue if acute interstitial nephritis, cutaneous/systemic lupus erythematosus occurs. Long-term therapy may lead to malabsorption/deficiency of Vit. B12. Increased risk of osteoporosis-related fractures (hip, wrist or spine) with long-term and multiple daily dose PPI therapy. Monitor magnesium levels with long-term therapy. Use lowest effective dose for shortest duration. Reevaluate periodically. IV: consider zinc supplementation in those prone to zinc deficiency. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions:

Concomitant atazanavir or nelfinavir: not recommended. May alter absorption of gastric pH-dependent drugs (eg, ketoconazole, iron, atazanavir, erlotinib, mycophenolate mofetil, ampicillin). Concomitant digoxin, diuretics may predispose patients to hypomagnesemia. Monitor warfarin. May give antacids concomitantly. May potentiate methotrexate (consider temporary withdrawal of the PPI); monitor. May cause false (+) urine THC test. IV: caution with concomitant other EDTA-containing products.

See Also:

PROTONIX TABLETS

PROTONIX for ORAL SUSP

Pharmacological Class:

Proton pump inhibitor.

Adverse Reactions:

Headache, diarrhea, nausea, vomiting, flatulence, dizziness, arthralgia, inj site reactions; also children: fever, rash, abdominal pain; rare: hypomagnesemia (w. prolonged PPI therapy); possible C. difficile-associated diarrhea.

Metabolism:

Hepatic (CYP2C19, 3A4). 98% protein bound.

Elimination:

Renal (primarily), fecal.

Generic Availability:

Tabs, IV (YES); oral soln (NO)

How Supplied:

Tabs—90; Susp—30 packets/box; Vials (40mg)—1, 10, 25